Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Teleflex Medical
EY’s M&A Firepower report predicts very active M&A activity for medtechs in 2021, driven by diagnostics and digital health, but with some headwinds remaining.
Urology device developer NeoTract, which Teleflex purchased in 2017, is now under scrutiny for potential FCA violations.
Story and Podcast: Teleflex Medical launched in March a novel portfolio of miniaturized percutaneous surgical instruments that have the same functionality as full-sized laparoscopic instruments, but allow surgeons to access the abdominal cavity using trocar-less entry and much smaller incisions than those required in traditional laparoscopy. Teleflex execs say the technology is a game changer, and the company hopes percutaneous laparoscopy will become the standard of care for the 4 million laparoscopic procedures performed annually in the US.
Twelve FDA close-out letters were released in September.
- Surgical Equipment & Devices